It seems that this Merck’s pill does the same thing as sotrovimab that Australia is getting.
Both focus on mild or moderate COVID to reduce the chance of progressing to severe cases.
And sotrovimab seems to be more effective. It claims to reduce hospitalisation or death by 79%, while Merck’s pill reduces by 50%.
But Merck’s pill seems getting more media coverage and attention, because it’s US pharma, not sure…
MSB focuses on severe cases so again not direct competition. There’s still no effective treatment for severe COVID.
Also MSB said it’s expecting FDA feedback re clbp and chf in this quarter. Does that mean MSB already had meeting with FDA and just waiting for their decision about approval pathway going forward?
It seems that this Merck’s pill does the same thing as...
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15990 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 48632 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |